Combination therapy improves survival for certain prostate cancer patients

	Tweet

Men with localized prostate cancer who were treated with male hormone suppression therapy and radiation treatment had longer survival, but those with moderate to high levels of other illnesses did not experience this effect, according to a study in the January 23 issue of JAMA.

Several studies have documented increased survival when androgen (male sex hormone) suppression therapy (AST) is combined with external beam radiation therapy (RT) compared with RT alone in the treatment of unfavorable localized and locally advanced prostate cancer. However, comorbid (co-existing) illnesses may increase the negative effects of specific anti-cancer treatments such as AST, altering the survival benefit observed when AST is added to RT.

Anthony V. D’Amico, M.D., Ph.D., of Brigham and Women’s Hospital and Dana Farber Cancer Institute, Boston, and colleagues performed an analysis of overall survival of 206 men with localized but unfavorable–risk prostate cancer in subgroups defined by their level of comorbidity at the time of their randomization to AST and RT vs. RT alone. During a median follow-up of 7.6 years, 74 deaths occurred. 

Estimates of overall survival were significantly higher for men who were randomized to RT and AST compared with RT. The cumulative incidence estimates of prostate cancer–specific mortality significantly favored the RT and AST group, with an increased risk of prostate cancer–specific mortality (14 vs. 4 deaths) that translated into an increased risk of all-cause mortality (44 vs. 30 deaths) in men randomized to RT compared with RT and AST.

A significant interaction was noted between comorbidity score and treatment. For the 157 men with no or minimal comorbidity scores, treatment with RT and AST compared with RT was associated with a significantly higher survival (31 vs. 11 deaths). Among the 49 men with moderate or severe comorbidity, those randomized to RT alone vs. RT and AST did not have an increased risk of all-cause mortality (13 vs. 19 deaths).

“The clinical significance of this finding is that pre-existing comorbid illness may increase the negative effects of specific anti-cancer treatments such as AST,” the authors write.

“In conclusion, the addition of 6 months of AST to RT resulted in increased overall survival in men with localized but unfavorable–risk prostate cancer. This result may pertain only to men without moderate or severe comorbidity, but this requires further assessment in a clinical trial specifically designed to assess this interaction.”

###

(JAMA. 2008;299[3]:289-295. Available pre-embargo to the media at www. jamamedia.org)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Contact: Lori Shanks
617-534-1604
JAMA and Archives Journals

RELATED STORIES:
Genetic mutations associated with increased PSA and prostate cancer   Possible link found between x-rays and prostate cancer   New type of adult stem cells found in the prostate may be involved in prostate cancer development   Accurate Prostate Cancer Diagnosis Depends on Biopsy Location   STD confirmed to be associated with increased risk of prostate cancer   Immunologic tests detect hidden prostate cancer   No link between alcohol and prostate cancer risk   Abbott says access to prostate cancer drug widened   Heavy drinking may boost prostate cancer risk   Surgeon’s skill affects prostate cancer relapse   Heavy men fare poorly with prostate cancer   Prostate Cancer Treatment Increases Risk of Diabetes and Heart Disease   Overweight men risk prostate cancer recurrence   Exercise Reduces Death Rate in Prostate Cancer Patients   Newly Discovered Gene Fusion May Lead to Improved Prostate Cancer Diagnosis   Drug Shows Activity in Men with Advanced Prostate Cancer   Prostate cancer hormone therapy hard on the heart   Hormonal Dietary Supplements Might Promote Prostate Cancer Progression   Variances in patterns of care for patients with prostate cancer failing primary therapy   U.S. Trial Shows No Early Mortality Benefit from Annual Prostate Cancer Screening   Being active may ward off prostate cancer death   Don’t Give Up on Prostate Cancer Screening Just Yet

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]